Drug Trial Radar · NCT06989359
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Apr 30, 2030
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- ADARx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Conditions
- IgAN
- C3G
- Complement-mediated Kidney Disease
- IgA Nephropathy (IgAN)
- IC-MPGN
Interventions
ADX-038 Dose Level 2Drug
siRNA duplex oligonucleotide
ADX-038 Dose Level 1Drug
siRNA duplex oligonucleotide
ADX-038 Dose Level 3Drug
siRNA duplex oligonucleotide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of ADX-038Time frame: Length of study - From Day 1 through Month 24
Locations
38 sites in 8 countries. Site status is shown where the registry gives one.
ADARx Clinical Site
Doral, Florida · Withdrawn
ADARx Clinical Site
Miami, Florida · Recruiting
ADARx Clinical Site
Pembroke Pines, Florida · Withdrawn
ADARx Clinical Site
Iowa City, Iowa · Recruiting
ADARx Clinical Site
Shreveport, Louisiana · Withdrawn
ADARx Clinical Site
Shelby, Michigan · Recruiting
ADARx Clinical Site
Great Neck, New York · Recruiting
ADARx Clinical Site
Columbus, Ohio · Recruiting
ADARx Clinical Site
Dakota Dunes, South Dakota · Recruiting
ADARx Clinical Site
Dallas, Texas · Withdrawn
ADARx Clinical Site
Houston, Texas · Recruiting
ADARx Clinical Site
Sydney, Australia · Recruiting
ADARx Clinical Site
Woolloongabba, Australia · Recruiting
ADARx Clinical Site
Liverpool, New South Wales, Australia · Recruiting
ADARx Clinical Site
Wollongong, New South Wales, Australia · Recruiting
ADARx Clinical Site
Hong Kong, Hong Kong · Recruiting
ADARx Clinical Site
Shatin, Hong Kong · Recruiting
ADARx Clinical Site
Bergamo, Italy · Recruiting
ADARx Clinical Site
Bologna, Italy · Recruiting
ADARx Clinical Site
Pavia, Italy · Recruiting
ADARx Clinical Site
Cheonan, South Korea · Recruiting
ADARx Clinical Site
Daegu, South Korea · Recruiting
ADARx Clinical Site
Gyeonggi-do, South Korea · Recruiting
ADARx Clinical Site
Seoul, South Korea · Recruiting
ADARx Clinical Site
Seoul, South Korea · Recruiting
ADARx Clinical Site
Seoul, South Korea · Recruiting
ADARx Clinical Site
Seoul, South Korea · Recruiting
ADARx Clinical Site
Wŏnju, Gangwon-do, South Korea · Recruiting
ADARx Clinical Site
Gyeonggi-do, Gurogu, South Korea · Recruiting
ADARx Clinical Site
Seoul, Gurogu, South Korea · Recruiting
ADARx Clinical Site
Barcelona, Spain · Recruiting
ADARx Clinical Site
Madrid, Spain · Recruiting
ADARx Clinical Site
Madrid, Spain · Recruiting
ADARx Clinical Site
Seville, Spain · Recruiting
ADARx Clinical Site
Kaohsiung City, Taiwan · Not yet recruiting
ADARx Clinical Site
New Taipei City, Taiwan · Recruiting
ADARx Clinical Site
Newcastle upon Tyne, United Kingdom · Recruiting
ADARx Clinical Site
Leicester, BC, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.